← Back to Search

Home Transfusion Program for Blood Cancers

N/A

Waitlist Available

Led By Oreofe Odejide, MD, MPH

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of a relapsed/refractory hematologic malignancy

Age ≥ 18 years

Must not have

Age < 18 years (for Caregivers)

Age < 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is investigating whether a new program called HEME-Hospice, which allows patients to receive blood transfusions at home, can improve the quality of life, mood, and end-of-life

Who is the study for?

This trial is for patients with blood-related cancers like leukemia, myelodysplastic syndrome, multiple myeloma, and lymphoma. Participants should be in need of hospice care and could benefit from home blood transfusions.

What is being tested?

The study is testing a new HEME-Hospice Program that offers home blood transfusions to see if it improves quality of life, mood, and reduces hospital visits at the end of life compared to usual care.

What are the potential side effects?

Since this trial involves standard home blood transfusions as part of hospice care rather than a drug or medical procedure, side effects may include typical transfusion-related reactions such as fever or allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My blood cancer has returned or is not responding to treatment.

Select...

I am 18 years old or older.

Select...

I've had a blood transfusion since my blood cancer diagnosis without severe reactions.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am a caregiver and I am under 18 years old.

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hospice Enrollment Rate

Length of Hospice Enrollment

Secondary study objectives

Caregiver Anxiety Symptoms

Caregiver Depression Symptoms

Caregiver Quality of Life

+10 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm 1: Access to home blood transfusions while enrolled in hospice (HEME-Hospice care)Experimental Treatment1 Intervention

Participants assigned to access to HEME-Hospice care who enroll in hospice will have at least once weekly assessment of symptoms of anemia and thrombocytopenia by the study team and will receive transfusions at home as indicated. Individualized care appointments with hospice care team providers, and frequency of visits are determined by individual participant need.

Group II: Arm 2: Usual CareActive Control1 Intervention

Participants assigned to usual care will receive standard oncology care delivered by the hematologic oncologists. Participants will have access to regular/standard hospice care if they elect to enroll in hospice.

0 / 6Eligibility criteria met